Biosimilars are gaining ground. The IRA could push them even further next year.

When biosimilars crashed into AbbVie’s Humira in 2023, the pricing impact was mostly negligible. Now, that’s beginning to change, and the Inflation Reduction Act could exacerbate how biosimilars affect branded medications, potentially slashing billions from healthcare costs.